Miles Wang became an OpenAI researcher in 2024 after leaving Harvard without finishing his degree.
The new startup builds AI models designed to discover drugs.
Wang is not the first OpenAI researcher to jump into this space. Josh Meier, another former OpenAI researcher, co-founded Chai Discovery two years ago. That startup secured $400 million and was valued at $3.8 billion. Then there is Isomorphic Labs, a spinout from Google DeepMind, which closed a $2.1 billion Series B round in May 2026.
All these companies share a similar pitch: use AI to find drugs faster and cheaper than traditional methods.
The advantage is speed. Developing a brand-new drug from scratch can take a decade. Repurposing something that already passed safety tests can generate revenue much sooner.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
Despite the enthusiasm, the field remains nascent. Many AI-driven drug discovery efforts have yet to produce a marketed drug, and the gap between computational predictions and clinical reality is wide. Wang's venture, like its predecessors, will need to navigate complex regulatory pathways and demonstrate real-world efficacy before its valuation can be justified by tangible results.
Nothing is final, and numbers could change. Wang himself disputed the reported funding figures and the description of his company in the original article.
He did not offer correct numbers or details, though. Lightspeed did not respond to a request for comment.
So this is a real story with some uncertainty baked in. The deal could close at a different valuation, or it could fall apart. That is normal at this stage.
The bottom line: Even with the caveats, the sheer size of these early-stage numbers tells you something. Venture capital is betting billions that AI can transform the way we find new medicines.
You cannot buy shares in Wang's startup yet. It is private. But the trend matters for anyone invested in biotech or AI. When top talent leaves a company like OpenAI to start a drug discovery firm, and when investors slap a $2 billion price tag on it before it has a single product, that is a signal.
Public companies that work on AI for drug discovery - or that partner with these startups - could see more attention. So could biotech ETFs that hold a basket of the biggest names in the space. At the same time, most drug discovery startups fail. The science is hard, and AI is not magic.
For a curious investor, the smart move is to watch. The money flowing into this area is real. The talent is real.
But the winners are not obvious yet. Keep an eye on which companies start signing deals with these new AI-driven biotech firms. That is often where the public market opportunity shows up first.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
